Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Activity of EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT07607054 is registered in ClinicalTrials.gov with Shanghai EpimAb Biotherapeutics Co., Ltd. as lead sponsor.

NCT NCT07607054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07607054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Activity of EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 26, 2026
Completion date
October 30, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors